Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 6/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30923993 | 0.81 | ALDH1A1 (0.32) | NR1H2MEN1KMT2A | |
| SCHEMBL27219708 | 0.77 | — | — | |
| SCHEMBL30923988 | 0.77 | NR1H2 (0.36) | NR1H2TACR1MEN1KMT2A | |
| SCHEMBL30923948 | 0.76 | PARP1 (0.40) | NR1H2TACR1KDM1A | |
| SCHEMBL30957911 | 0.76 | PARP1 (0.40) | NR1H2TACR1KDM1A | |
| SCHEMBL29134449 | 0.76 | NR1H2 (0.42) | NR1H2TACR1MEN1KMT2ACHRM2 | |
| SCHEMBL29770799 | 0.76 | NR1H2 (0.42) | NR1H2TACR1MEN1KMT2ACHRM2 | |
| SCHEMBL16749570 | 0.75 | NR1H2 (0.42) | NR1H2TACR1MEN1KMT2ACHRM2 | |
| SCHEMBL16914071 | 0.74 | NR1H2 (0.40) | NR1H2TACR1MEN1KMT2ACHRM2 | |
| SCHEMBL30636995 | 0.73 | NR1H2 (0.49) | NR1H2TACR1MEN1KMT2ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122071471-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-22 | — | — | CN | disclosed |
| CN-122010946-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| CN-122010945-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| US-12534471-B2 | Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-27 | — | — | US | disclosed |
| EP-4612145-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2025-09-10 | — | — | EP | disclosed |
| US-20240317765-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-26 | — | — | US | disclosed |
| US-20240174677-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-30 | — | — | US | disclosed |
| WO-2024095133-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317765-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NPY2R | NR1H2 170/4885TACR1 38/4885KDM1A 473/4885 |
| US-20240174677-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NPY2R | NR1H2 170/4885TACR1 38/4885KDM1A 473/4885 |
| US-12534471-B2 | Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof | HCRTR2, HCRTR1, NPY1R | NR1H2 79/4885TACR1 128/4885KDM1A 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.